Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Research And Development Expense of $106.24 million for the year ending 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -2.4% in Research And Development Expense from 2024 to 2025.
- This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 202.2%.
- Historical annual values: Fiscal year 2025: $106.24 million | Fiscal year 2024: $108.80 million | Fiscal year 2023: $91.59 million | Fiscal year 2022: $74.55 million | Fiscal year 2021: $90.47 million | Fiscal year 2020: $75.96 million | Fiscal year 2019: $69.10 million | Fiscal year 2018: $89.21 million | Fiscal year 2017: $49.58 million | Fiscal year 2016: $42.79 million | Fiscal year 2015: $29.14 million | Fiscal year 2014: $19.59 million | Fiscal year 2013: $17.25 million | Fiscal year 2012: $23.52 million | Fiscal year 2011: $30.63 million | Fiscal year 2010: $35.15 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: